抗毒素の世界市場レポート 2024年

抗毒素市場規模は近年力強く成長しています。2023年の18億米ドルから2024年には19億4,000万米ドルへと、CAGR7.9％で成長します。過去の期間に観察された成長は、ヘビ咬傷の高い発生率、毒ヘビの地理的分布、特定の地域における医療施設への限られたアクセス、曝露の増加に寄与する農業および農村活動、ヘビ咬傷事故への対処を目的とした公衆衛生イニシアチブを含むいくつかの要因に起因します。これらの要因が複合的に、過去の時間枠における抗毒素の使用および関連する医療介入の拡大に一役買っています。

抗毒素市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR7.0％で25億5,000万米ドルに成長します。今後予想される成長には、気候変動がヘビの生息地に与える影響、ヘビと遭遇しやすい地域の人口増加、抗毒素製剤の進歩、世界の健康安全保障を推進する取り組み、抗毒素開発のための共同作業など、さまざまな要因が考えられます。予測期間中に予想される主な動向には、有効性向上のためのデータ分析の統合、教育・訓練プログラムへの重点化、生産規模拡大のための戦略的提携、規制枠組みの改善、新規治療ターゲットに焦点を当てた調査などがあります。これらの動向は、ヘビ咬傷事故への対処における技術革新と進歩の機会を提供し、この分野の成長を形成・促進する態勢を整えています。

ヘビ咬傷の発生件数の増加は、当面の抗毒素市場の拡大に拍車をかけると予想されます。ヘビに咬まれると、毒ヘビに含まれる毒素によって重症化し、致命的な状態に至る可能性があります。抗毒素は特殊な治療薬であり、適切な治療量を迅速に投与することで、ヘビ咬傷に伴うほとんどの症状を緩和または回復させる可能性を持っています。例えば、2021年5月に世界保健機関（WHO）が強調したように、年間推定540万件のヘビ咬傷が発生し、180万～270万件のenvenoming（ヘビ咬傷による中毒）につながっています。さらに、これらの事故は年間約81,000～138,000人の命を奪い、その3倍の数の切断や重傷をもたらしています。したがって、ヘビによる咬傷の発生率の上昇は、抗毒素市場の成長を促進する重要な要因となっています。

研究開発レベルの向上は、抗毒素市場の拡大を促進します。抗毒素領域における継続的な研究イニシアチブは、より洗練された効果的な製剤の探求と開発に貢献しています。科学者と製薬会社の共同作業を通じて、抗毒素製品の有効性、安全性、特異性を高め、治療結果の改善と副作用の最小化を目指す努力が続けられています。例えば、2021年4月にNatural Library of Medicine誌に掲載された知見では、スリランカ産のコブラ（Naja naja）の毒によって誘発されるin vitroでの筋毒性を予防または回復させるという良好な結果が強調されています。この結果は、VINSとBharatという2種類のインド製多価抗毒素を使用したもので、コブラ咬傷の予防的治療における可能性を示すものです。したがって、研究開発活動の機運の高まりが、抗毒素市場の成長の原動力となっています。

2023年の世界の抗毒素市場規模では、北米が最大地域でした。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。抗毒素市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の抗毒素市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 一価
• 多価
• その他のタイプ
• 世界の抗毒素市場、動物別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• ヘビ
• サソリ
• 蜘蛛
• その他
• 世界の抗毒素市場、作用機序別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 細胞毒性
• 神経毒性
• 止血性
• 心毒性
• 筋毒性
• 他の動作モード
• 世界の抗毒素市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 病院
• クリニック
• 外来手術センター
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の抗毒素市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の抗毒素市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗毒素市場の競合情勢
• 抗毒素市場の企業プロファイル
  • Pfizer Inc.
  • Commonwealth Serum Laboratories
  • Merck KGaA
  • Incepta Pharmaceuticals Limited
  • Bharat Serums and Vaccines Limited

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

“Antivenom Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antivenom market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antivenom? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The antivenom market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Monovalent; Polyvalent; Other Types
• 2) By Animal: Snakes; Scorpions; Spiders; Other Animals
• 3) By Mode of Action: Cytotoxic; Neurotoxic; Hemotoxic; Cardiotoxic; Myotoxic; Other Modes Of Action
• 4) By End User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
• Companies Mentioned: Pfizer Inc.; Commonwealth Serum Laboratories; Merck KGaA; Incepta Pharmaceuticals Limited; Bharat Serums and Vaccines Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Antivenom, also referred to as antivenin, is an antibody therapy designed to neutralize the toxins present in specific venoms when administered promptly after a bite. It is commonly employed in the treatment of poisonous animal bites or stings, such as those inflicted by rattlesnakes, moccasins, and copperheads.

The primary categories of antivenom include monovalent, polyvalent, and others. Monovalent antivenom is a specialized formulation crafted to counteract the effects of venom from a single species of snake or a specific toxin. These formulations are utilized to address venoms produced by a variety of animals, including snakes, scorpions, spiders, among others. They operate through diverse modes of action, such as cytotoxic, neurotoxic, hemotoxic, cardiotoxic, myotoxic, and others. These antivenom therapies are utilized by various end-users, including hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The antivenom market research report is one of a series of new reports from The Business Research Company that provides antivenom market statistics, including antivenom industry global market size, regional shares, competitors with a antivenom market share, detailed antivenom market segments, market trends and opportunities, and any further data you may need to thrive in the antivenom industry. This antivenom market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antivenom market size has grown strongly in recent years. It will grow from $1.8 billion in 2023 to $1.94 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth observed during the historical period can be attributed to several factors, including the high incidence of snakebites, the geographic distribution of venomous snakes, limited access to medical facilities in certain regions, agricultural and rural activities contributing to increased exposure, and public health initiatives aimed at addressing snakebite incidents. These factors collectively played a role in the expansion of antivenom usage and related medical interventions during the historical timeframe.

The antivenom market size is expected to see strong growth in the next few years. It will grow to $2.55 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The anticipated growth in the upcoming period can be attributed to various factors, including the impact of climate change on snake habitats, population growth in regions prone to snake encounters, advancements in antivenom formulations, initiatives promoting global health security, and collaborative efforts for the development of antivenom. Major trends expected in the forecast period include the integration of data analytics for enhanced efficacy, a heightened focus on education and training programs, strategic alliances to scale up production, improvements in regulatory frameworks, and research focused on novel therapeutic targets. These trends are poised to shape and drive growth in the field, providing opportunities for innovation and advancements in addressing snakebite incidents.

The rise in the occurrence of snake bites is anticipated to fuel the expansion of the antivenom market in the foreseeable future. Snake bites can result in severe illnesses caused by toxins present in the bite of venomous snakes, potentially leading to fatal conditions. Antivenom, a specialized treatment administered promptly and in adequate therapeutic doses, holds the potential to mitigate or reverse most symptoms associated with snakebite envenoming. For example, as highlighted by the World Health Organization (WHO) in May 2021, an estimated 5.4 million snake bites take place annually, leading to 1.8 to 2.7 million instances of envenoming (poisoning from snake bites). Moreover, these incidents claim the lives of approximately 81,000 to 138,000 individuals yearly and result in three times the number of amputations and severe injuries. Hence, the escalating incidence of snake bites is a significant driver propelling the growth of the antivenom market.

The escalating level of research and development endeavors is poised to advance the expansion of the antivenom market. Continuous research initiatives in the antivenom domain contribute to the exploration and development of more sophisticated and efficacious formulations. Through collaborative efforts between scientists and pharmaceutical companies, there's a concerted effort to heighten the effectiveness, safety, and specificity of antivenom products, aiming for improved treatment outcomes and minimized adverse effects. For instance, findings published in a journal by the Natural Library of Medicine in April 2021 highlighted positive outcomes in preventing or reversing in vitro myotoxicity induced by the venom of the common cobra (Naja naja) from Sri Lanka. This was achieved using two Indian polyvalent anti-venoms, specifically VINS and Bharat, showcasing their potential in proactively treating cobra bites. Therefore, the increasing momentum in research and development activities serves as a driving force behind the growth of the antivenom market.

Product innovation stands as a significant trend making headway in the antivenom market. Companies operating within this sector are investing in the development of pioneering products to maintain their market positions. For example, in April 2021, Rare Disease Therapeutics, Inc., a US-based pharmaceutical company, unveiled Antivenom ANAVIP, a novel FDA-approved medication with expanded indications. This antivenom is authorized to treat pit viper bites in both adults and children, covering venomous snakes such as rattlesnakes, copperheads, and cottonmouth/water moccasins. Engineered with a prolonged half-life, its design aims to reduce the likelihood of re-emerging venom effects, such as platelet drops, prolonged bleeding times, and other abnormal blood coagulation tests, which previously necessitated additional doses of shorter-acting antivenom formulations.

Major enterprises within the antivenom market are forging strategic partnerships to foster innovation and fortify their market presence. An illustrative instance is the collaboration between Bharat Serums and Vaccines Limited, an India-based pharmaceutical company, and the Indian Institute of Science (IISc) Bengaluru, a public university in India. Their partnership, established in August 2022, endeavors to advance the development of antivenoms tailored to specific regions. The joint effort seeks to pioneer the next generation of snakebite therapy in India by addressing the complexities stemming from variations in venoms across snake species and within regions. Present treatments predominantly rely on a single polyvalent antivenom designed for the country's 'big four' snakes, revealing limitations in efficacy as indicated by recent research. The collaboration focuses on creating region-specific antivenoms to elevate the effectiveness of snakebite therapy and ultimately save lives.

In March 2021, SERB Specialty Pharmaceuticals, a Belgium-based specialty pharmaceutical company focusing on prescription treatments for rare and life-threatening diseases, successfully acquired BTG Specialty Pharmaceutical for an undisclosed amount. This strategic acquisition represents a significant expansion for SERB, enhancing and diversifying its portfolio by incorporating a global specialty pharmaceutical company. BTG Specialty Pharmaceuticals, based in the United States, is recognized for its expertise in critical care medications and has a growing presence in the field of rare diseases. Notably, BTG Specialty Pharmaceuticals is known for its development of snakebite antivenom drugs.

Major companies operating in the antivenom market report are Pfizer Inc., Commonwealth Serum Laboratories, Merck KGaA, Incepta Pharmaceuticals Limited, Bharat Serums and Vaccines Limited, Rare Disease Therapeutics Inc., Vins Bioproducts Limited, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Haffkine Bio-Pharmaceutical Corporation Limited, MicroPharm Limited, Latoxan SAS, Serum Institute of India Pvt. Ltd., BSV Group, Shanghai Serum Biotech Co Ltd., British Technology Group International, South African Vaccine Producers, Bioclon Institute, Inosan Biopharma, Instituto Bioclon S.A. de C.V., F. Hoffmann-La Roche AG, Protherics Inc., Sanofi Pasteur SA, Venom Supplies Pty Ltd, Instituto Clodomiro Picado, Laboratorios Silanes S.A. de C.V., Instituto Biologico Argentino S.A., Instituto Vital Brazil, Instituto Butantan, Instituto Nacional de Produccion de Biologicos, Instituto de Biotecnologia de la UNAM,

North America was the largest region in the global antivenom market size in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antivenom market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antivenom market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The antivenom market consists of sales of taipan antivenom and death adder antivenom. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Antivenom Market Characteristics

3. Antivenom Market Trends And Strategies

4. Antivenom Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Antivenom Market Size and Growth

• 5.1. Global Antivenom Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Antivenom Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Antivenom Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Antivenom Market Segmentation

• 6.1. Global Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Monovalent
• Polyvalent
• Other Types
• 6.2. Global Antivenom Market, Segmentation By Animal, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Snakes
• Scorpions
• Spiders
• Other Animals
• 6.3. Global Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Cytotoxic
• Neurotoxic
• Haemotoxic
• Cardiotoxic
• Myotoxic
• Other Modes Of Action
• 6.4. Global Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Other End-Users

7. Antivenom Market Regional And Country Analysis

• 7.1. Global Antivenom Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Antivenom Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Antivenom Market

• 8.1. Asia-Pacific Antivenom Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Antivenom Market

• 9.1. China Antivenom Market Overview
• 9.2. China Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Antivenom Market

• 10.1. India Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Antivenom Market

• 11.1. Japan Antivenom Market Overview
• 11.2. Japan Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Antivenom Market

• 12.1. Australia Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Antivenom Market

• 13.1. Indonesia Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Antivenom Market

• 14.1. South Korea Antivenom Market Overview
• 14.2. South Korea Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Antivenom Market

• 15.1. Western Europe Antivenom Market Overview
• 15.2. Western Europe Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Antivenom Market

• 16.1. UK Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Antivenom Market

• 17.1. Germany Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Antivenom Market

• 18.1. France Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Antivenom Market

• 19.1. Italy Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Antivenom Market

• 20.1. Spain Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Antivenom Market

• 21.1. Eastern Europe Antivenom Market Overview
• 21.2. Eastern Europe Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Antivenom Market

• 22.1. Russia Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Antivenom Market

• 23.1. North America Antivenom Market Overview
• 23.2. North America Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Antivenom Market

• 24.1. USA Antivenom Market Overview
• 24.2. USA Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Antivenom Market

• 25.1. Canada Antivenom Market Overview
• 25.2. Canada Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Antivenom Market

• 26.1. South America Antivenom Market Overview
• 26.2. South America Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Antivenom Market

• 27.1. Brazil Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Antivenom Market

• 28.1. Middle East Antivenom Market Overview
• 28.2. Middle East Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Antivenom Market

• 29.1. Africa Antivenom Market Overview
• 29.2. Africa Antivenom Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Antivenom Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Antivenom Market Competitive Landscape And Company Profiles

• 30.1. Antivenom Market Competitive Landscape
• 30.2. Antivenom Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Commonwealth Serum Laboratories
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck KGaA
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Incepta Pharmaceuticals Limited
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bharat Serums and Vaccines Limited
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Antivenom Market Competitive Benchmarking

32. Global Antivenom Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Antivenom Market

34. Antivenom Market Future Outlook and Potential Analysis

• 34.1 Antivenom Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Antivenom Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Antivenom Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer